Teachers Retirement System of The State of Kentucky Trims Stake in Catalent, Inc. (NYSE:CTLT)

Teachers Retirement System of The State of Kentucky lessened its position in Catalent, Inc. (NYSE:CTLT) by 8.4% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 13,501 shares of the company’s stock after selling 1,233 shares during the quarter. Teachers Retirement System of The State of Kentucky’s holdings in Catalent were worth $817,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently made changes to their positions in CTLT. Brooklyn Investment Group bought a new position in Catalent in the third quarter worth $31,000. Sentry Investment Management LLC purchased a new stake in shares of Catalent in the 3rd quarter worth about $53,000. Longfellow Investment Management Co. LLC increased its stake in shares of Catalent by 45.7% in the 2nd quarter. Longfellow Investment Management Co. LLC now owns 972 shares of the company’s stock worth $55,000 after acquiring an additional 305 shares in the last quarter. Thurston Springer Miller Herd & Titak Inc. lifted its position in Catalent by 57.5% during the 3rd quarter. Thurston Springer Miller Herd & Titak Inc. now owns 1,181 shares of the company’s stock valued at $72,000 after acquiring an additional 431 shares during the period. Finally, Intact Investment Management Inc. bought a new stake in Catalent during the third quarter worth about $73,000.

Catalent Price Performance

Catalent stock opened at $63.48 on Thursday. Catalent, Inc. has a 12 month low of $41.15 and a 12 month high of $63.50. The stock has a fifty day simple moving average of $60.41 and a two-hundred day simple moving average of $59.18. The company has a current ratio of 2.51, a quick ratio of 1.96 and a debt-to-equity ratio of 1.38. The firm has a market cap of $11.52 billion, a price-to-earnings ratio of -28.09, a PEG ratio of 2.70 and a beta of 1.15.

Catalent (NYSE:CTLT) last released its quarterly earnings data on Tuesday, November 5th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of $0.05 by ($0.18). The business had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.06 billion. Catalent had a negative return on equity of 0.66% and a negative net margin of 9.28%. Catalent’s quarterly revenue was up 4.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.10) earnings per share. Equities analysts predict that Catalent, Inc. will post 0.78 EPS for the current fiscal year.

Insider Transactions at Catalent

In related news, insider David Mcerlane sold 1,994 shares of Catalent stock in a transaction on Thursday, September 26th. The stock was sold at an average price of $59.97, for a total value of $119,580.18. Following the completion of the sale, the insider now owns 36,304 shares of the company’s stock, valued at $2,177,150.88. The trade was a 5.21 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Michelle R. Ryan sold 2,800 shares of the stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $59.70, for a total value of $167,160.00. Following the completion of the transaction, the director now directly owns 10,835 shares in the company, valued at approximately $646,849.50. This represents a 20.54 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 5,114 shares of company stock worth $305,931 over the last three months. 0.31% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

CTLT has been the subject of several recent research reports. Baird R W lowered shares of Catalent from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 24th. Robert W. Baird reaffirmed a “neutral” rating and set a $63.50 price objective on shares of Catalent in a research report on Tuesday, September 24th. William Blair reissued a “market perform” rating on shares of Catalent in a report on Tuesday, September 3rd. Finally, StockNews.com downgraded Catalent from a “hold” rating to a “sell” rating in a report on Tuesday, December 10th. One equities research analyst has rated the stock with a sell rating and seven have issued a hold rating to the company. According to MarketBeat.com, Catalent has a consensus rating of “Hold” and a consensus price target of $63.40.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.